Payment overview · 2025
General Payments
$33.65
2 reported records · 2 companies
Healthcare provider profile · identity verified
Muhammad Mirza, MBBS
Allopathic & Osteopathic Physicians|Family Medicine · CENTERVILLE, TN · NPI 1255541918
Verified facts
What the public records show
CMS Open Payments records show Muhammad Mirza, MBBS received $33.65 in general payments during 2025 across 2 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.21 | 54.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.44 | 45.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.65 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 151 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 453 | 84 |
| Gabapentin | Gabapentin | 442 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 112 |
| Lisinopril | Lisinopril | 336 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 68 |
| Furosemide | Furosemide | 268 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 72 |
| Omeprazole | Omeprazole | 239 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 66 |
| Eliquis | Apixaban | 231 | 34 |
| Metformin Hcl | Metformin Hcl | 227 | 63 |
| Potassium Chloride | Potassium Chloride | 216 | 71 |
| Losartan Potassium | Losartan Potassium | 211 | 67 |
| Simvastatin | Simvastatin | 180 | 46 |
| Meloxicam | Meloxicam | 175 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 48 |
| Famotidine | Famotidine | 164 | 55 |
| Mirtazapine | Mirtazapine | 164 | 32 |
| Trazodone Hcl | Trazodone Hcl | 159 | 38 |
| Carvedilol | Carvedilol | 147 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 53 |
| Montelukast Sodium | Montelukast Sodium | 138 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 32 |
| Linzess | Linaclotide | 110 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 32 |
| Tramadol Hcl | Tramadol Hcl | 109 | 18 |
| Donepezil Hcl | Donepezil Hcl | 105 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 17 |
| Ozempic | Semaglutide | 98 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 28 |
| Xarelto | Rivaroxaban | 97 | 14 |
| Allopurinol | Allopurinol | 94 | 16 |
| Alprazolam | Alprazolam | 94 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 20 |
| Jardiance | Empagliflozin | 90 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 11 |
| Spironolactone | Spironolactone | 85 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 13 |
| Ondansetron Odt | Ondansetron | 73 | 39 |
| Memantine Hcl | Memantine Hcl | 71 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 21 |
| Buspirone Hcl | Buspirone Hcl | 67 | 12 |
| Finasteride | Finasteride | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 16 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 15 |
| Celecoxib | Celecoxib | 57 | 17 |
| Levetiracetam | Levetiracetam | 56 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Prednisone | Prednisone | 52 | 33 |
| Glipizide | Glipizide | 51 | 16 |
| Lorazepam | Lorazepam | 51 | 13 |
| Dexamethasone | Dexamethasone | 48 | 40 |
| Nystatin | Nystatin | 48 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 12 |
| Fluconazole | Fluconazole | 46 | 17 |
| Valacyclovir | Valacyclovir Hcl | 46 | suppressed |
| Atenolol | Atenolol | 45 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 12 |
| Meclizine Hcl | Meclizine Hcl | 45 | 18 |
| Clonidine Hcl | Clonidine Hcl | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 30 |
| Lactulose | Lactulose | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 17 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 11 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Novolog Flexpen | Insulin Aspart | 36 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 12 |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 25 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Klor-Con 10 | Potassium Chloride | 27 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 20 |
| Methocarbamol | Methocarbamol | 24 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Torsemide | Torsemide | 19 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Prevacid | Lansoprazole | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.65 · 2 records | Bayer Healthcare Pharmaceuticals Inc. | ADCETRIS, ELREXFIO, Nubeqa | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error